Sidney Wolfe writes in the BMJ - AllTrials - Selective clinical trial reporting: betraying trial participants, harming patients

< h1 class="title" style="font: -apple-system-headline; font-weight: normal; -webkit-hyphens: manual; max-width: 100%;" > < br > < /h1 > < span style="max-width: 100%; -webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > < /span > < div style="max-width: 100%;" > < p style="max-width: 100%;" > < span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > Reporting biases found in trials of cardiovascular devices < /span > < /p > < /div > < p style="max-width: 100%;" > < span style="-webkit-text-size-adjust: auto; background-color: rgba(255, 255, 255, 0);" > Reporting biases in published trials were first identified in 1986. < span class="converted-anchor" style="max-width: 100%;" > 1 < /span > & nbsp;Published randomized studies of combination chemotherapy compared with treatment with an alkylating agent as first line treatment for ovarian cancer showed a significant survival advantage for combination chemotherapy. Unpublished cancer trial registry data from the same studies, however, showed no such advantage. < span class="converted-anchor" style="max-width: 100%;" > 2 < /span > & nbsp;Similarly, in the treatment of multiple myeloma, registry data suggested a smaller survival advantage for combination chemotherapy (over prednisone and an alkylating agent) than the results of published studies. The author who reported the discrepancy concluded that his findings “demonstrate the value and importance of an international reg...

Source: PharmaGossip - June 10, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs